Condition: Acute Ischemic Stroke · Sponsor: Kunming Pharmaceuticals, Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.
This description comes directly from the study's public registry record.
Duo Gao, bachelor · 0871-68319868-3052 · GAODUO5@kpc.com.cn
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hosptial,Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Shenzhen Second People's Hospital | Shenzhen, Guangdong, China | Recruiting |
| Cangzhou Central Hospital | Cangzhou, Hebei, China | Recruiting |
| Hengshui People's Hospital | Hengshui, Hebei, China | Recruiting |
| Da Qing Long Nan Hospital | Daqing, Heilongjiang, China | Recruiting |
| Daqing Oilfield General Hospital | Daqing, Heilongjiang, China | Recruiting |
| The People's Hospital Of Anyang City | Anyang, Henan, China | Recruiting |
| Nanshi Hospital Of Nanyang | Nanyang, Henan, China | Recruiting |
| Nanyang Second General Hospital | Nanyang, Henan, China | Recruiting |
| The First Affiliated Hospital Of Nanyang Medical College | Nanyang, Henan, China | Recruiting |
| Xuzhou Central Hospital | Xuzhou, Jiangsu, China | Recruiting |
| Meihakou Central Hospital | Meihekou, Jilin, China | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.